Novartis AG (NOVN.SW)
| Previous Close | 91.23 |
| Open | 91.11 |
| Bid | 92.40 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 90.78 - 93.80 |
| 52 Week Range | 79.21 - 94.52 |
| Volume | |
| Avg. Volume | 3,356,932 |
| Market Cap | 190.105B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 23.18 |
| EPS (TTM) | 4.02 |
| Earnings Date | Jul 18, 2024 |
| Forward Dividend & Yield | 3.30 (3.54%) |
| Ex-Dividend Date | Mar 07, 2024 |
| 1y Target Est | 86.92 |
ZacksNovartis (NVS) Reports Positive Long-Term Data on CSU Drug
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
GlobeNewswireNovartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs. investigator-selected SoC TKIs (imatinib, nilotinib, dasatinib and bosutinib) (67.7% vs. 49.0%) and imatinib alone (69.3% vs. 40.2%)1 Scemblix also demonstrated a favorable safety and tolerability profile vs. imatinib and 2G TKIs, with fewer grade ≥3 AEs, dose adjustments, and half the rate of AEs leading to tr
- GlobeNewswire
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, demonstrated a favorable and consistent safety profile up to 1 year, including balanced liver function tests versus placebo1Novartis intends to submit remibrutinib for approval in chronic spontaneous urticaria (CSU) to global health authorities starting in H2 2024, and continu
